LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD
Market Cap: 45.8m USD

LAVA Therapeutics NV
Net Issuance of Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

LAVA Therapeutics NV
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Net Issuance of Common Stock
$27k
CAGR 3-Years
-93%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Net Issuance of Common Stock
$17.1m
CAGR 3-Years
120%
CAGR 5-Years
68%
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Net Issuance of Common Stock
€71.8m
CAGR 3-Years
464%
CAGR 5-Years
8%
CAGR 10-Years
84%
Uniqure NV
NASDAQ:QURE
Net Issuance of Common Stock
$415m
CAGR 3-Years
538%
CAGR 5-Years
142%
CAGR 10-Years
10%
argenx SE
XBRU:ARGX
Net Issuance of Common Stock
$309.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Net Issuance of Common Stock
$354.7m
CAGR 3-Years
24%
CAGR 5-Years
36%
CAGR 10-Years
21%
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
45.8m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.52 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Net Issuance of Common Stock?
Net Issuance of Common Stock
27k USD

Based on the financial report for Dec 31, 2024, LAVA Therapeutics NV's Net Issuance of Common Stock amounts to 27k USD.

What is LAVA Therapeutics NV's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
-93%

The average annual Net Issuance of Common Stock growth rates for LAVA Therapeutics NV have been -93% over the past three years .

Back to Top